Distinguishing benign from malignant liver tumours

Cancer Imaging

Volumn 7, Issue SPEC. ISS. A, 2007, Pages

  Heiken, Jay P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Focal nodular hyperplasia; Hepatic hemangioma; Hepatocellular adenoma; Liver neoplasms

Indexed keywords

ERYTHROCYTE TC 99M; ETIFENIN TC 99M; GADOBENIC ACID; GADOLINIUM; GADOXETIC ACID; MANGAFODIPIR; ORAL CONTRACEPTIVE AGENT; PERTECHNETIC ACID TC 99M; SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; BENIGN TUMOR; BIOPSY TECHNIQUE; CANCER CLASSIFICATION; CANCER INVASION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HEMANGIOMA; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER TUMOR; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME; LIVER ADENOMA; PATHOLOGY; REVIEW;

ADENOMA, LIVER CELL; DIAGNOSIS, DIFFERENTIAL; FOCAL NODULAR HYPERPLASIA; HEMANGIOMA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 35848943264     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2007.9084     Document Type: Article

References (132)

1. Karhunen PJ. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol 1986; 39: 183-8.
2. Wright TL, Venook AP, Millward-Sadler GH. GH M-S. Hepatic tumours. In: Millward-Sadler GH, Wright R, Arthur MJP, editors. Wright's liver and biliary disease, vol 2. 3rd ed. Philadelphia: WB Saunders; 1992, p. 1079-21.
3. Gibney RG, Hendin AP, Cooperberg PL. Sonographically detected hepatic hemangiomas: absence of change over time. AJR Am J Roentgenol 1987; 149: 953-7.
4. Mungovan JA. Cronan JJ, Vacarro, J. Hepatic cavernous hemangiomas: lack of enlargement over time. Radiology 1994; 191: 111-13.
5. Nghiem HV, Bogost GA, Ryan JA, Lund P, Freeny PC, Rice KM. Cavernous hemangiomas of the liver: enlargement over time. AJR Am J Roentgenol 1997; 169: 137-40.
6. Takayasu K, Makuuchi M, Takayama T. Computed tomography of a rapidly growing hepatic hemangioma. J Comput Assist Tomogr 1990; 14: 143-5.
7. Stephens DH, Johnson CD. Benign masses of the liver. In: Silverman PM, Zeman RK, editors. CT and MRI of the liver and biliary system. Fishman EK, series editor. Contemporary issues in computed tomography, vol 12. New York. Churchill Livingstone; 1990, p. 93-127.
8. Whitehouse RW. Computed tomography attenuation measurements for the characterization of hepatic haemangiomas. Br J Radiol 1991; 64: 1019-22.
9. Ashida C, Fishman EK, Zerbouni EA, Herlong FH, Siegelman SS. Computed tomography of hepatic cavernous hemangioma. J Comput Assist Tomogr 1987; 11: 455-60.
10. Freeny PC, Marks WM. Hepatic hemangioma: dynamic bolus CT. AJR Am J Roentgenol 1986; 147: 711-19.
11. Itai Y, Furui S, Araki T, Yashiro N, Tasaka A. Computed tomography of cavernous hemangioma of the liver. Radiology 1980; 137: 149-55.
12. Leslie DF, Johnson CD, MacCarty RL, Ward EM, Ilstrup DM, Harmsen WS. Single-pass CT of hepatic tumors: value of globular enhancement in distinguishing hemangiomas from hypervascular metastases. AJR Am J Roentgenol 1995; 165: 1403-6.
13. Quinn SF, Benjamin GG. Hepatic cavernous hemangiomas: simple diagnostic sign with dynamic bolus CT. Radiology 1992; 182: 545-8.
14. Leslie DF, Johnson CD, MacCarty RL, et al. Distinction between cavernous hemangiomas of the liver and hepatic metastases on CT: value of contrast enhancement patterns. AJR Am J Roentgenol 1995: 164: 625-9.
15. Hanafusa K, Ohashi I, Himeno Y, Suzuki S, Shibuya H. Hepatic hemangioma: findings with two-phase CT. Radiology 1995; 196: 465-9.
16. Gaa J, Saini S, Ferrucci JT. Perfusion characteristics of hepatic cavernous hemangioma using intravenous CT angiography (IVCTA). Eur J Radiol 1991; 12: 228-33.
17. Itai Y, Teraoka T. Angiosarcoma of the liver mimicking cavernous hemangioma on dynamic CT. J Comput Assist Tomogr 1989; 13: 910-12.
18. Mahony B, Jeffrey RB, Federle MP. Spontaneous rupture of hepatic and splenic angiosarcoma demonstrated by CT. AJR Am J Roentgenol 1982; 138: 965-6.
19. Vasile N, Larde D, Zafrani ES, Berard H, Mathien D. Hepatic angiosarcoma, J Comput Assist Tomogr 1983; 7: 899-901.
20. Koyama T, Fletcher JG, Johnson CD, Kio MS, Notohara K, Burgart LJ. Primary hepatic angiosarcoma: findings at CT and MR imaging. Radiology 2002; 222: 667-73.
21. Peterson MS, Baron RL, Rankin SC. Hepatic angiosarcoma: findings on multiphasic contrast-enhanced helical CT do not mimic hepatic hemangioma. AJR Am J Roentgenol 2000; 175: 165-70.
22. McFarland EG, Mayo-Smith WW, Saini S, Hahn PF, Goldberg MA., Lee MJ. Hepatic hemangiomas and malignant tumors: improved differentiation with heavily T2-weighted conventional spin-echo MR imaging. Radiology 1994; 193: 43-7.
23. Ohtomo Y. Itai Y, Furui S, Yashiro N, Yoshikawa K, Iio M. Hepatic tumors: differentiation by transverse relaxation time (T2) of magnetic resonance imaging. Radiology 1985; 155: 421-3.
24. Ohtomo K, Itai Y, Yoshikawa K, Kokubo T, Iio M. Hepatocellular carcinoma and cavernous hemangioma: differentiation with MR imaging. Efficacy of T2 values at 0.35 and 1.5 T. Radiology 1988; 168: 621-3.
25. Stark DD, Felder RC, Wittenberg J, et al. Magnetic resonance imaging of cavernous hemangioma of the liver: tissue-specific characterization. AJR Am J Roentgenol 1985; 145: 213-22.
26. Choi BI, Han MC, Kim CW. Small hepatocellular carcinoma versus small cavernous hemangioma: differentiation with MR imaging at 2.0 T. Radiology 1990; 176: 103-6.
27. Glazer GM, Aisen AM, Francis IR, Gyves JW, Lande I, Adler DD. Hepatic cavernous hemangioma: magnetic resonance imaging. Work in progress. Radiology 1985; 155: 417-20.
28. Itai Y, Ohtomo Y, Furui S. Yamauchi T, Minami M, Yashiro N. Noninvasive diagnosis of small cavernous - hemangioma of the liver: advantage of MRI. AJR Am J Roentgenol 1985; 145: 1195-9.
29. Lombardo DM, Baker ME, Spritzer CE, Blinder R, Meyers W, Herfkens RJ. Hepatic hemangiomas vs metastases: MR differentiation at 1.5 T. AJR Am J Roentgenol 1990; 155: 55-9.
30. Choi BI. Han MC, Park JH, Kim SH, Han MH, Kim CW. Giant cavernous hemangioma of the liver: CT and MR imaging in 10 cases. AJR Am J Roentgenol 1989; 152: 1221-6.
31. Ros PR, Lubbers PR, Olmsted WW, Morillo G. Hemangioma of the liver: heterogeneous appearance on T2-weighted images. AJR Am J Roentgenol 1987; 149: 1167-70.
32. Mirowitz SA, Lee JK, Heiken JP. Cavernous hemangioma of the liver: assessment of MR tissue specificity with a simplified T2 index. J Comput Assist Tomogr 1990: 14: 223-8.
33. Ohtomo K, Itai Y, Yoshida H, Kokubo T, Yoshikawa K, Iio, M. MR differentiation of hepatocellular carcinoma from cavernous hemangioma: complementary roles of FLASH and T2 values. AJR Am J Roentgenol 1989; 152: 505-7.
34. Birnbaum BA, Weinreb JC, Megibow AJ, et al. Definitive diagnosis of hepatic hemangiomas: MR imaging versus Tc-99m-labeled red blood cell SPECT. Radiology 1990; 176: 95-101.
35. Li KC, Glazer, GM, Quint LE, et al. Distinction of hepatic cavernous hemangioma from hepatic metastases with MR imaging. Radiology 1988; 169: 409-15.
36. Rummeny E, Saini S, Wittenberg J, et al. MR imaging of liver neoplasms. AJR Am J Roentgenol 1989; 152: 493-9.
37. Berger JF, Laissy J-P, Llmot O, et al. Differentiation between multiple liver hemangiomas and liver metastases of gastrinomas: value of enhanced MRI. J Comput Assist Tomogr 1996; 20: 349-55.
38. Mitchell DG, Saini S, Weinreb J, et al. Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Radiology 1994; 193: 49-57.
39. Soyer P, Gueye C, Soniveille E, Laisay JP, Scherrer A. MR diagnosis of hepatic metastases from neuroendocrine tumors versus hemangiomas: relative merits of dynamic gadolinium chelate-enhanced gradient-recalled echo and unenhanced spin-echo images. AJR Am J Roentgenol 1995; 165: 1407-13.
40. Whitney WS, Herfkens RJ, Jeffrey RB, et al. Dynamic breath-hold multiplanar spoiled gradient-recalled MR imaging with gadolinium enhancement for differentiating hepatic hemangiomas from malignancies at 1.5 T. Radiology 1993; 189: 863-70.
41. Jang HJ, Choi BI, Kim TK, et al. Atypical small hemangiomas of the liver: 'bright dot' sign at two-phase spiral CT. Radiology 1998; 208: 543-8.
42. Vilgrain V, Boulos L, Vullierme MP, Denys A, Terris B, Menu Y. Imaging of atypical hemangiomas of the liver with pathologic correlation. Radiographics 2000; 20: 379-97.
43. Mitsudo K, Watanabe Y, Saga T, et al. Nonenhanced hepatic cavernous hemangionia with multiple calcifications: CT and pathologic correlation. Abdom Imaging 1995; 20: 459-61.
44. Scatarige JC, Fishman EK, Saksouk FA, Siegelman SS. Computed tomography of calcified liver masses. J Comput Assist Tomogr 1983; 7: 83-9.
45. Brancatelli G, Federle MP, Blachar A, Grazioli L. Hemangioma in the cirrhotic liver: diagnosis and natural history. Radiology 2001; 219: 69-74.
46. Cheng HC, Tsai SH, Chiang JH, Chang CY. Hyalinized liver hemangioma mimicking malignant tumor at MR imaging. AJR Am J Roentgenol 1995; 165: 1016-17.
47. Takayasu K, Moriyama N, Shima Y, et al. Atypical radiographic findings in hepatic cavernous hemangioma: correlation with histologic features. AJR Am J Roentgenol 1986; 146: 1149-53.
48. Tung GA. Vaccaro JP, Cronan JJ, Rogg JM. Cavernous hemangioma of the liver: pathologic correlation with high-field MR imaging. AJR Am J Roentgenol 1994; 162: 1113-17.
49. Leifer DM, Middleton WD, Teefey SA, Menias CO, Leahy JR. Follow-up of patients at low risk for hepatic malignancy with a characteristic hemangioma at US. Radiology 2000; 214: 167-72.
50. Kudo M, Ikekubo K, Yamamoto K, et al. Distinction between hemangioma of the liver and hepatocellular carcinoma: value of labeled RBC-SPECT scanning. AJR Am J Roentgenol 1989; 152: 977-83.
51. Tumeh SS, Benson C, Nagel JS, English RJ, Holman BL. Cavernous hemangioma of the liver: detection with single-photon emission computed tomography. Radiology 1987; 164: 353-6.
52. Craig J, Peters R, Edmonson H. Tumors of the liver and intrahepatic bile ducts (second series). Atlas of tumor pathology, vol fascicle 26. Washington, DC: Armed Forces Institute of Pathology, 1989.
53. Carlson SK, Johnson CD, Bender CE, Welch TJ. CT of focal nodular hyperplasia of the liver. AJR Am J Roentgenol 2000; 174: 76-12.
54. Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999; 23: 1441-54.
55. Vilgrain V, Flejou JF, Arrive L, et al. Focal nodular hyperplasia of the liver. MR imaging and pathologic correlation in 37 patients. Radiology 1992; 184: 699-703.
56. Buetow PC, Pantongrag-Brown L, Buck JL, Ros PR, Goodman ZD. Focal nodular hyperplasia of the liver: radizologic-pathologic correlation. Radiographics 1996; 16: 369-88.
57. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985; 5: 1194-200.
58. Knowles 2nd DM, Casarella WJ, Johnson PM, Wolff M. The clinical, radiologic, and pathologic characterization of benign hepatic neoplasms. Alleged association with oral contraceptives. Medicine (Baltimore) 1979; 57: 223-37.
59. Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981; 1: 116-28.
60. Leconte I, Van Beers BE, Lacrosse M, et al. Focal nodular hyperplasia: natural course observed with CT and MRI. J Comput Assist Tomogr 2000; 24: 61-6.
61. Nakayama T, Hiyama Y, Ohnishi K. et al. Arterioportal shunts on dynamic computed tomography. AJR Am J Roentgenol 1983; 140: 953-7.
62. Nime F, Pickren JW, Vana J, Aronoff BL, Baker HW, Murphy GP. The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. Cancer 1979; 44: 1481-9.
63. Ross D, Pina J, Mirza M, Galvan A, Ponce L. Letter: Regression of focal nodular hyperplasia after discontinuation of oral contraceptives. Ann Intern Med 1976; 85: 203-4.
64. Weimann A, Mossinger M, Fronhoff K, Nadalin S, Raab R. Pregnancy in women with observed focal nodular hyperplasia of the liver. Lancet 1998; 351: 1251-2.
65. Mathieu D, Kobeiter H, Cherqui D, Rahmouni A, Dhumeaux D. Oral contraceptive intake in women with focal nodular hyperplasia of the liver. Lancet 1998; 352: 1679-80.
66. Mathieu D, Bruneton JN, Drouiliard J, Pointreau CC, Vasile N. Hepatic adenomas and focal nodular hyperplasia: dynamic CT study. Radiology 1986; 160: 53-8.
67. Shamsi K, De Schepper A, Degryse H, Dockers F. Focal nodular hyperplasia of the liver: radiologic findings. Abdom Imaging 1993; 18: 32-8.
68. Welch TJ, Sheedy 2nd PF, Johnson CM, et al. Focal nodular hyperplasia and hepatic adenoma: comparison of angiography, CT, US, and scintigraphy. Radiology 1985; 156: 593-5.
69. Brancatelli G, Federie MP, Katyal S, Kapoor V. Hemodynamic characterization of focal nodular hyperplasia using three-dimensional volume-rendered multidetector CT angiography. AJR Am J Roentgenol 2002; 179: 81-5.
70. Choi CS, Freeny PC. Triphasic helical CT of hepatic focal nodular hyperplasia: incidence of atypical findings. AJR Am J Roentgenol 1998; 170: 391-5.
71. Hussain SM, Terkivatan T, Zondervan PE, et al. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics 2004; 24: 3-17(discussion 18-19).
72. Mortele KJ, Pract M, Van Vlierberghe H, Kunnen M, Ros PR. CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation. AJR Am J Roentgenol 2000; 175: 687-92.
73. Mahfouz AE, Hamm B, Taupitz M, Wolf KJ. Hyperviscular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 186: 133-8.
74. Mattison GR, Glazer GM, Quint LE, Francis IR, Bree RL, Ensminger WD. MR Aging of hepatic focal nodular hyperplasia: characteription and distinction from primary malignant hepatic tumors. AJR Am J Roentgenol 1987; 148: 711-15.
75. Rummeny E, Weissleder R, Stark DD, et al. Primary liver tumors: diagnosis by MR imaging. AJR Am J Roentgenol 1989; 152: 63-72.
76. Schiebler ML, Kressel BY, Saul SH, Yeager BA, Axel L, Gefter WB. MR imaging of focal nodular hyperplasia of the liver. J Comput Assist Tomogr 190; 11: 651-4.
77. Chaoui A, Mergo PJ, Lauwers GY. Unusual appearance of focal nodular hyperplasia with fatty change. AJR Am J Roentgenol 1998; 171: 1433-4.
78. Mathieu D, Vilgrain V, Mahfouz AE, Anglade MC, Vullierme MP, Denys A. Benign liver tumors. Magn Reson Imaging Clin N Am 1997; 5: 255-88.
79. Prasad SR, Wang H, Rosas H, et al. Fat-containing lesions of the liver: radiologio-pathologic correlation. Radiographics 2005; 25: 321-31.
80. Rummeny E, Weissleder R, Sironi S, et al. Central scars in primary liver tumors: MR features, specificity, and pathologic correlation. Radiology 1989; 171: 323-6.
81. Mathieu D, Rahmouni A. Anglade MC, et al. Focal nodular hyperplasia of the liver: assessment with contrast-enhanced TurboFLASH MR imaging. Radiology 1991; 180: 25-30.
82. Coffin CM, Diche T, Mahfouz A, et al. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol 1999; 9: 444-9.
83. Rofsky NM, Weinreb J, Bernardino ME, et al. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. Radiology 1993; 188: 52-9.
84. Vogl TJ, Hamm B, Schnell B, et al. Mn-DPDP enhancement patterns on hepatocellular lesions on MR images. J Magn Reson Imaging 1993; 3: 51-8.
85. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001; 221: 731-9.
86. Grazioli L, Morana G, Kirchin MA, et al. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison. J Magn Reson Imaging 2003; 17: 593-602.
87. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral Cr-initial observations. Radiology 2005; 234: 468-78.
88. Grandin C, Van Beers BE, Robert A. Gigot JF, Geubel A, Pringot J. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration. J Comput Assist Tomogr 1995; 19: 412-18.
89. Paley MR, Mergo PJ, Torres GM, Ros PR. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weightcd MR imaging. AJR Am J Roentgenol 2000; 175: 159-63.
90. Precetti-Morel S, Bellin MF, Ghebontni L, et al. Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences. Eur Radiol 1999; 9: 1535-42.
91. Denys A. Arrive L, Servois V, et al. Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25. Radiology 1994; 193: 665-9.
92. Pauleit D, Textor J, Bachmann R, et al. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 2002; 222: 73-80.
93. Tang Y, Yamashita Y, Arakawa A, et al. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumaxides-enhanced MR imaging. AJR Am J Roentgenol 1999; 112: 1547-54.
94. Vogl TJ, Hammerstingl R, Schwarz W, et al. Superparamagnetic iron oxido-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 1996; 198: 881-7.
95. Yamamoto H, Yamashita Y, Yoshimatsu S, Baba Y, Takahashi M. MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles. J Comput Assist Tomogr 1995; 19: 665-7.
96. Caseiro-Alves F, Zins M, Mahfouz AE, et al. Calcification in focal nodular hyperplasia: a new problem for differentiation from fibrolamellar hepatocellular carcinoma. Radiology 1996; 198: 889-92.
97. Stanley G, Jeffrey Jr RB, Feliz B. CT findings and histopathology of intratumoral steatosis in focal nodular hyperplasia: case report and review of the literature. J Comput Assist Tomogr 2002; 26: 815-17.
98. Hamrick-Turner JE, Shipkey FH, Cranston PE. Fibrolamellar hepatocellular carcinoma: MR appearance mimicking focal nodular hyperplasia. J Comput Assist Tomogr 1994; 18: 301-4.
99. Rogers JV, Mack LA, Freeny PC, Johnson ML, Sones PJ. Hepatic focal nodular hyperplasia: angiography, CT, sonography, and scintigraphy. AJR Am J Roentgenot 1981; 137: 983-90.
100. Kinnard MF, Alavi A. Rubin RA, Lichtenstein GR. Nuclear imaging of solid hepatic masses. Semin Roentgenol 1995; 30: 375-95.
101. Lubbers PR, Ros PP, Goodman ZD, Ishak KG. Accumulation of technetium-99m sulfur colloid by hepatocellular adenoma: scintigraphic-pathologic correlation. AJR Am J Roentgenol, 1987; 148: 1105-8.
102. Boulahdour H, Cherqui D, Charlotte F, et al. The hot spot hepatobiliary scan in focal nodular hyperplasia. J Nuci Med 1993; 34: 2105-10.
103. Kaji K, Kaneko S, Matsushita E, Kobayashi K, Matsui O, Nakanuma Y. A case of progressive multiple focal nodular hyperplasia with alteration of imaging studies. Am J Gastroenterol 1998; 93: 2568-72.
104. Goodman ZD, Mikel UV, Lubbers PP. Ros PR, Langloss JM, Ishak KG. Kupffer cells in hepatocellular adenomas. Am J Surg Pathol 1987; 11: 191-6.
105. Kerlin P, Davis GL, McGill DB, Weiland LH, Adson MA, Sheedy 2nd PF. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 1983; 84: 994-1002.
106. Ichikawa T, Federle MP, Grazioli L, Nalesnik M. Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology 2000; 214: 861-8.
107. Paulson EV, McClellan JS, Washington K, Spritzer CE, Meyers WC, Baker ME. Hepatic adenoma: MR characteristics and correlation with pathologic findings. AJR Am J Roentgenol 1994; 163: 113-16.
108. Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976; 294: 470-2.
109. Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology 1977; 73: 386-94.
110. Edmondson HA, Reynolds TB, Henderson B, Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977; 86: 180-2.
111. Kawakatsu M, Vilgrain V, Erlinger S, Nahum H. Disappearance of liver cell adenoma: Cr and MR imaging. Abdorn Imaging 1997; 22: 274-6.
112. Mariani AF, Livingstone AS, Pereiras Jr RV, van Zuiden PE, Schiff ER. Progressive enlargement of an hepatic cell adenoma. Gastroenterology 1979; 77: 1319-25.
113. Boyd PP, Mark GJ. Multiple hepatic adenomas and a hepatocellular carcinoma in a man on oral methyl testosterone for eleven years. Cancer 1977; 40: 1765-70.
114. Coire CI, Qizilbash AH, Castelli MR Hepatic adenomata in type Ia glycogen storage disease. Arch Pathol Lab Med 1987; 111: 166-9.
115. Doppman JL, Cornblath M, Dwyer AJ, Adams AJ, Girton ME, Sidbury J. Computed tomography of the liver and kidneys in glycogen storage disease. J Comput Assist Tomogr 1982; 6: 67-71.
116. Leose T, Farges O, Bismuth H. Liver cell adenoqias. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988; 208: 558-64.
117. Limmer J, Fleig WE, Leupold D, Bittner R, Ditschuneit H, Beger HG. Hepatocellular carcinoma in type I glicogen storage disease. Hepatology 1988; 8: 531-7.
118. Miller JH, Stanley P, Gates GF. Radiology of glycogen storage diseases. AJR Am J Roentgenol 1979; 132: 379.
119. Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg 1994; 129: 712-17.
120. Gordon S, Reddy K, Livingstone A. Resolution of a contraceptive steroid induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986; 105: 547-9.
121. Neuberger J, Portmann B, Nunnerley HB, Laws JW, Davis M, Williams R. Oral-contraceptive-associated liver tumours: occurrence of malignancy and difficulties in diagnosis. Lancet 1980; 1: 273-6.
122. Tao LC. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer 1991; 68: 341-7.
123. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001; 21: 877-92 (discussion 892-74).
124. Ruppert-Kohlmayr A, Uggowitzer MM, Kugler C, Zebedin D, Schaffler G, Ruppert GS. Focal nodular hyperplasia and hepatocellular adenoma of the liver: differentiation with multiphasic helical Cr. AJR Am J Roentgenol 2001; 176: 1493-8.
125. Arrive L, Flejou JF, Vilgrain V, et al. Hepatic adenoma: MR findings in 51 pathologically proved lesions. Radiology 1994; 193: 507-12.
126. Chung KY, Mayo-Smith WW, Saini S, Rahmouni A. Goili M, Mathieu D. Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol 1995; 165: 303-8.
127. Flejou JF, Barge I, Menu Y, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 1985; 89: 1132-8.
128. Grazioli L, Federle MP, Ichikawa T, Balzano E, Nalesnik M, Madariaga J. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology 2000; 216: 395-402.
129. Ribeiro A. Burgart U, Nagorney DM, Gores GJ. Management of liver adenomatosis: results with a conservative surgical approach. Liver Transpl Surg 1998; 4: 388-98.
130. Mahfouz AE, Hamm B, Wolf KJ. Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology 1994; 190: 49-52.
131. Danet IM, Semelka RC, Leonardou P, et al. Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 2003; 181: 809-17.
132. Lee JKT, Sagel SS, Stanley RJ, Heiken JP, editors. Computed body tomography with MRI correlation. 4th ed. Philadelphia: Lippincott Williams & Wilkins: 2006.